Omega Therapeutics Reports Second Quarter 2021 Financial Results and Outlines Key Corporate Objectives
Omega Therapeutics (Nasdaq: OMGA) reported its second-quarter financial results for 2021, highlighting a net loss of $15.4 million, compared to $6.3 million in Q2 2020. The company raised $141.1 million through its IPO and is focused on advancing its lead candidate, OTX-2002, for hepatocellular carcinoma. As of June 30, 2021, Omega had cash and cash equivalents of $122.4 million. R&D expenses increased to $11.2 million, reflecting its commitment to product development. The company plans to file an IND for OTX-2002 in early 2022 and continue expanding its OMEGA Epigenomic Programming platform.
- Raised $141.1 million through IPO, enhancing financial resources.
- Advance OTX-2002 for hepatocellular carcinoma, with IND filing expected in H1 2022.
- Cash and equivalents of $122.4 million as of June 30, 2021.
- Net loss increased to $15.4 million from $6.3 million year-over-year.
- R&D expenses rose significantly by $6.3 million, indicating higher operational costs.
CAMBRIDGE, Mass., Sept. 10, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced financial results for the second quarter ended June 30, 2021.
"Our recent successful initial public offering (IPO) reinforces our commitment to bring potentially transformative programmable mRNA therapeutics that target the epigenetic basis of disease to precisely control gene expression to patients across a wide range of diseases. We are thrilled to bring in new investors through our IPO and to have the continued support of our existing stockholders," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. "The funding provides the necessary financial resources to advance our lead Omega Epigenomic Controller (OEC) candidate, OTX-2002, for the treatment of Hepatocellular Carcinoma through an Investigational New Drug (IND) filing and initial clinical readouts, as well as to continue pre-clinical and IND-enabling studies for several additional OEC development candidates."
Recent Business Highlights and Corporate Update
Financial and Corporate
- In August 2021, Omega completed a successful IPO, including shares sold pursuant to the partial exercise of the underwriters' option to purchase additional shares, raising
$141.1 million in aggregate gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, and listed on The Nasdaq Global Select Market. The IPO followed the closing of a Series C crossover financing of$126 million in gross proceeds in March 2021. - In May 2021, Luke Beshar was appointed to the Omega Board of Directors and currently serves as the Chair of the Audit Committee. Mr. Beshar is an industry and corporate finance veteran who currently serves on the Board of Directors of Trillium Therapeutics and Protara Therapeutics, and most recently served as Executive Vice President and Chief Financial Officer at NPS Pharmaceuticals, Inc., through its acquisition by Shire PLC.
- In March 2021, Elliott M. Levy, M.D., was appointed to the Omega Board of Directors and currently serves on the Nominating and Corporate Governance Committee. Dr. Levy is an industry veteran with over 20 years of senior leadership roles in research and development at global pharmaceutical companies, including Amgen and Bristol-Myers Squibb.
Development Pipeline and Platform
- OTX-2002: IND-enabling studies are ongoing for Omega's lead OEC candidate OTX-2002, a novel, engineered, and programmable mRNA therapeutic being developed for the downregulation of c-Myc oncogene expression in patients with hepatocellular carcinoma. In preclinical studies, OTX-2002 demonstrated its ability to potently down-regulate c-Myc oncogene expression. The Company continues to be on track to file an IND for OTX-2002 in the first half of 2022.
- OMEGA Epigenomic Programming Platform: Omega is creating a new generation of programmable mRNA therapeutics, one that is designed to enable control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega has developed a highly rational and deterministic approach to drug design that enables the Company to rapidly develop and optimize novel OECs engineered for highly specific targeting and controlled tunability and durability of gene expression. Omega is advancing multiple pre-clinical development programs in regenerative medicine, multigenic diseases including immunology, oncology and select monogenic diseases.
Milestones and Key Priorities
- Complete IND-enabling studies for OTX-2002 and successfully file IND application to FDA during the first half of 2022.
- Nominate additional OEC development candidates in the first half of 2022.
- File a second IND application targeted for second half of 2022.
- Continue to develop the OMEGA Epigenomic Programming platform and investigate additional development programs to expand pipeline.
- Publish relevant pre-clinical and early clinical data supporting our programs and platform development.
Second Quarter 2021 Financial Results
As of June 30, 2021, the Company had cash and cash equivalents totaling
Research and development (R&D) expenses for the second quarter of 2021 were
General and administrative expenses (G&A) for the second quarter of 2021 were
Net loss for the second quarter of 2021 was
About Omega Therapeutics
Omega Therapeutics is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform. The OMEGA™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's engineered, modular, and programmable mRNA-encoded epigenetic medicines, Omega Epigenomic Controllers™, target specific intervention points amongst the thousands of mapped and validated novel DNA-sequence-based epigenomic loci to durably tune single or multiple genes to treat and cure disease through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.
For more information, visit omegatherapeutics.com, or follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential of our product candidates, including our lead OEC candidate OTX-2002; development timelines; anticipated timing of regulatory submissions and filings; and expectations regarding our pipeline, including trial design, initiation of preclinical studies and our goal of declaring additional OEC development candidates. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the novel technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtaining regulatory approval, if at all; the substantial development and regulatory risks associated with epigenomic controller machines due to the novel and unprecedented nature of this new category of medicines; our limited operating history; the incurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future; our need for substantial additional financing; our investments in research and development efforts that further enhance the OMEGA platform, and their impact on our results; uncertainty regarding preclinical development, especially for a new class of medicines such as epigenomic controllers; the fact that our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences; the impact of increased demand for the manufacture of mRNA and LNP based vaccines to treat COVID-19 on our development plans; difficulties manufacturing the novel technology on which our OEC candidates are based; our ability to adapt to rapid and significant technological change; our reliance on third parties for the manufacture of materials; our ability to successfully acquire and establish our own manufacturing facilities and infrastructure; our reliance on a limited number of suppliers for lipid excipients used in our product candidates; our ability to advance our product candidates to clinical development; and our ability to obtain, maintain, enforce and adequately protect our intellectual property rights. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the period ended June 30, 2021 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Investor contact:
Kevin Murphy/Brendan Burns
Argot Partners
212.600.1902
ArgotOmega@argotpartners.com
Media contact:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com
Omega Therapeutics, Inc. | ||||||||||||||||
Condensed Statements of Operations and Comprehensive Loss | ||||||||||||||||
(in thousands, except share and per share amounts) | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Three months ended June 30, | Six months ended June 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | $ | 11,184 | $ | 4,895 | $ | 20,933 | $ | 8,416 | ||||||||
General and administrative | 3,637 | 1,010 | 6,452 | 2,375 | ||||||||||||
Related party expense, net | 384 | 225 | 763 | 567 | ||||||||||||
Total operating expenses | 15,205 | 6,130 | 28,148 | 11,358 | ||||||||||||
Loss from operations | (15,205) | (6,130) | (28,148) | (11,358) | ||||||||||||
Other expense, net: | ||||||||||||||||
Interest expense, net | (190) | (194) | (402) | (387) | ||||||||||||
Change in fair value of warrant liability | (11) | 1 | (340) | 4 | ||||||||||||
Other expense, net | (4) | — | (8) | — | ||||||||||||
Total other expense, net | (205) | (193) | (750) | (383) | ||||||||||||
Net loss and comprehensive loss | $ | (15,410) | $ | (6,323) | $ | (28,898) | $ | (11,741) | ||||||||
Net loss per common stock attributable to common stockholders, basic and diluted | $ | (3.36) | $ | (1.58) | $ | (6.36) | $ | (2.99) | ||||||||
Weighted-average common stock used in net loss per share attributable to common stockholders, basic and diluted | 4,588,500 | 4,007,606 | 4,542,832 | 3,929,900 | ||||||||||||
Omega Therapeutics, Inc. | ||||||||
Condensed Balance Sheets | ||||||||
(in thousands, except share and per share amounts) | ||||||||
(Unaudited) | ||||||||
June 30, | December 31, | |||||||
2021 | 2020 | |||||||
Assets | ||||||||
Cash and cash equivalents | $ | 122,411 | $ | 22,951 | ||||
Other assets | 7,635 | 5,132 | ||||||
Total assets | $ | 130,046 | $ | 28,083 | ||||
Liabilities, redeemable convertible preferred stock, and stockholders' deficit | ||||||||
Liabilities | $ | 21,937 | $ | 17,486 | ||||
Redeemable convertible preferred stock | 200,593 | 75,225 | ||||||
Stockholders' deficit | (92,484) | (64,628) | ||||||
Total liabilities, redeemable convertible preferred stock, and stockholders' deficit | $ | 130,046 | $ | 28,083 | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/omega-therapeutics-reports-second-quarter-2021-financial-results-and-outlines-key-corporate-objectives-301373124.html
SOURCE Omega Therapeutics
FAQ
What were Omega Therapeutics' financial results for Q2 2021?
How much capital did Omega Therapeutics raise in its IPO?
What is the status of Omega Therapeutics' lead candidate OTX-2002?
What are the research and development expenses for Omega Therapeutics in Q2 2021?
